18 August 2023 - Teclistamab, the first BCMA-targeting bispecific antibody to receive approval in Europe, maintained deep and durable responses, with reduced onset of Grade 3 or higher infections, in eligible patients with relapsed and refractory multiple myeloma switching from weekly to reduced, biweekly dosing schedule.

Janssen announced today that the European Commission has granted the approval of a type II variation application for Tecvayli (teclistamab), providing the option for a reduced dosing frequency of 1.5mg/kg every two weeks in patients who have achieved a complete response or better for a minimum of six months.

Read Janssen press release